EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSCHYG00000008513
Gene Symbol: PDE9A
1 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSCHYG00000020787
Gene Symbol: PIK3R1
1 Cross references
259 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSCHYG00000020125
Gene Symbol: PIK3R2
1 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSCHYG00000025628
Gene Symbol: PIK3R3
1 Cross references
276 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSCHYG00000020002
Gene Symbol: PIK3R5
1 Cross references
255 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSCHYG00000004312
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSCHYG00000004014
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSCHYG00000009263
Gene Symbol: PLA2G10
1 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSCHYG00000021617
Gene Symbol: GART
1 Cross references
247 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSCHYG00000026485
Gene Symbol: PLAT
1 Cross references
203 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSCHYG00000013443
Gene Symbol: PDGFRA
1 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSCHYG00000004180
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).